Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Hydantoin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | MB | P02144 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydantoin SCHEMBL16971290 | 0.88 | CRBN (0.42) | CRBNMBALDH1A1CYP1A2HPGD | |
| Hydantoin SCHEMBL17274233 | 0.86 | CRBN (0.41) | CRBNMBALDH1A1CYP1A2HPGD | |
| Hydantoin SCHEMBL27705088 | 0.84 | CRBN (0.52) | CRBNMBALDH1A1CYP1A2HPGD | |
| Hydantoin SCHEMBL27690 | 0.84 | — | — | |
| Hydantoin SCHEMBL7285865 | 0.84 | — | — | |
| Hydantoin SCHEMBL1996688 | 0.83 | CRBN (0.42) | CRBNMB | |
| Hydantoin SCHEMBL1899774 | 0.82 | — | — | |
| Hydantoin SCHEMBL1786052 | 0.82 | — | — | |
| Hydantoin SCHEMBL10770473 | 0.82 | — | — | |
| Hydantoin SCHEMBL10578141 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112111560-B | DNA nanosphere and preparation method and application thereof | 深圳华大智造科技股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-112111560-A | DNA nanosphere and preparation method and application thereof | 深圳华大智造科技有限公司 | 2020-12-22 | — | — | CN | disclosed |
| EP-2025350-A3 | Determining pH by CEDST MRI | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2009-12-09 | — | — | EP | disclosed |
| EP-2025350-A2 | Determining pH by CEDST MRI | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20080167549-A1 | Method for enhancing contrast produced by MRI | THE GOV'T. OF THE U.S.A., AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2008-07-10 | — | — | US | disclosed |
| US-6963769-B1 | Method for enhancing contrast produced by MRI | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050059881-A1 | Method for enhancing contrast produced by MRI | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY | 2005-03-17 | — | — | US | disclosed |
| EP-1404372-A1 | PHARMACEUTICAL FORMULATIONS AND LIGANDS FOR USE THEREIN; MIMETICS FOR UEA-1 | Sarlan, Ltd. (BM) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003004062-A9 | PHARMACEUTICAL FORMULATIONS AND LIGANDS FOR USE THEREIN; MIMETICS FOR UEA-1 | SARLAN LTD | 2003-04-10 | — | — | WO | disclosed |
| WO-2003004062-A1 | PHARMACEUTICAL FORMULATIONS AND LIGANDS FOR USE THEREIN; MIMETICS FOR UEA-1 | SARLAN, LTD. (BM) | 2003-01-16 | — | — | WO | disclosed |
| EP-1178837-A2 | METHOD FOR ENHANCING CONTRAST PRODUCED BY MRI | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000066180-A3 | METHOD FOR ENHANCING CONTRAST PRODUCED BY MRI | US GOV HEALTH & HUMAN SERV (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2000066180-A8 | METHOD FOR ENHANCING CONTRAST PRODUCED BY MRI | US GOV HEALTH & HUMAN SERV (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2000066180-A2 | METHOD FOR ENHANCING CONTRAST PRODUCED BY MRI | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH (US) | 2000-11-09 | — | — | WO | disclosed |